J. Novotny

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

C. Horak, H. Inzunza, C. Harbison, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project

F. Hirsch, K. Kerr, M. Tsao, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Clive R. Taylor, J. Taube, C. Horak, 2013 .

OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057

S. Peters, E. Felip, H. Borghaei, 2017 .

Assay performance of the PD-L1 IHC 28-8 pharmDx assay in squamous cell carcinoma of the head and neck (SCCHN).

S. Álvarez, H. Inzunza, E. Oroudjev, 2017 .

Development of a diagnostic PD-L1 immunohistochemical assay for nivolumab therapy in urothelial carcinoma.

H. Inzunza, E. Oroudjev, J. Novotny, 2017 .

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

Xiaoling Zhang, H. Inzunza, J. Cogswell, 2015, Applied immunohistochemistry & molecular morphology : AIMM.

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma

Clive Taylor, Henrik Winther, Xiaoling Zhang, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1

H. Inzunza, J. Cogswell, G. Mintier, 2016, Molecular Diagnosis & Therapy.

A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.

H. Lenz, S. Tejpar, J. Novotny, 2020, Journal of Clinical Oncology.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group.

Donald W. Hutcheson, W. Levine, S. Morse, 1998, The Journal of infectious diseases.